CinRx has teamed with Sam Waksal’s Graviton Bioscience to advance ROCK2-focused therapeutics for pulmonary arterial hypertension and other cardiovascular indications. The partnership expands Graviton’s development strategy beyond its earlier ROCK2 work associated with the chronic graft-versus-host disease medicine Rezurock.